155 related articles for article (PubMed ID: 17634535)
21. [Analysis of prognostic factors of epithelial ovarian carcinoma].
Shao SL; Liu XS
Zhonghua Fu Chan Ke Za Zhi; 2010 Feb; 45(2):132-6. PubMed ID: 20420785
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic factors in ovarian epithelial cancer].
Nishida T
Gan To Kagaku Ryoho; 1996 May; 23(6):805-9. PubMed ID: 8645035
[TBL] [Abstract][Full Text] [Related]
23. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
24. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
25. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
26. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
[TBL] [Abstract][Full Text] [Related]
27. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
Kohn EC; Sarosy GA; Davis P; Christian M; Link CE; Ognibene FP; Sindelar WF; Jacob J; Steinberg SM; Premkumar A; Reed E
Gynecol Oncol; 1996 Aug; 62(2):181-91. PubMed ID: 8751547
[TBL] [Abstract][Full Text] [Related]
28. [Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer].
Qiao YH; Cheng J; Guo RX
Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):325-9. PubMed ID: 17673045
[TBL] [Abstract][Full Text] [Related]
29. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.
Baekelandt MM; Holm R; Nesland JM; Tropé CG; Kristensen GB
Anticancer Res; 2000; 20(2B):1061-7. PubMed ID: 10810398
[TBL] [Abstract][Full Text] [Related]
30. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma.
Reiter R; Gais P; Jütting U; Steuer-Vogt MK; Pickhard A; Bink K; Rauser S; Lassmann S; Höfler H; Werner M; Walch A
Clin Cancer Res; 2006 Sep; 12(17):5136-41. PubMed ID: 16951231
[TBL] [Abstract][Full Text] [Related]
31. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
32. GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer.
Kolwijck E; Zusterzeel PL; Roelofs HM; Hendriks JC; Peters WH; Massuger LF
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2176-81. PubMed ID: 19661073
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0).
Sakuragi N; Yamada H; Oikawa M; Okuyama K; Fujino T; Sagawa T; Fujimoto S
Gynecol Oncol; 2000 Nov; 79(2):251-5. PubMed ID: 11063653
[TBL] [Abstract][Full Text] [Related]
34. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma.
Sasaki N; Kudoh K; Kita T; Tsuda H; Furuya K; Kikuchi Y
J Obstet Gynaecol Res; 2007 Feb; 33(1):17-23. PubMed ID: 17212661
[TBL] [Abstract][Full Text] [Related]
35. Correlation between Aurora-A expression and the prognosis of cervical carcinoma patients.
Zhang W; Wang J; Liu SJ; Hua W; Xin XY
Acta Obstet Gynecol Scand; 2009; 88(5):521-7. PubMed ID: 19306133
[TBL] [Abstract][Full Text] [Related]
36. The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival.
Cantrell LA; Westin SN; Van Le L
Cancer; 2011 Mar; 117(6):1220-6. PubMed ID: 21381011
[TBL] [Abstract][Full Text] [Related]
37. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
[TBL] [Abstract][Full Text] [Related]
38. Centrosome-, chromosomal-passenger- and cell-cycle-associated mRNAs are differentially regulated in the development of sporadic colorectal cancer.
Gerlach U; Kayser G; Walch A; Hopt U; Schulte-Mönting J; Werner M; Lassmann S
J Pathol; 2006 Mar; 208(4):462-72. PubMed ID: 16402339
[TBL] [Abstract][Full Text] [Related]
39. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
40. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]